Tufts CSDD data shows no outsourcing model wins on speed or quality. Executive Director Ken Getz explains what matters more.
- What Happens When Acquisition Due Diligence Ignores Clinical Operations?
- Who's Wearing The Patient Recruitment Hat When Your Trial Decisions Are Made?
- Why Radioligand Therapy Studies Look Nothing Like Standard Oncology Phase 1s
- Years Before Clinical Trials: The Decisions That Shape The Future Of Academic Cancer Discoveries
- Two Parallel Trials, A Potential New Option For Protection From COVID-19
- The 2026 Pharma R&D AI Sourcing Map: Partnerships, Concentration, Inflection
- Firsthand Findings: How Incannex Is Designing Trials That Support Regulatory Approval
GUEST COLUMNISTS
-
Firsthand Findings: How Incannex Is Designing Trials That Support Regulatory Approval
Incannex CEO Joel Latham explains how thoughtful trial design and dose optimization can turn promising data into an approval-ready strategy.
-
The 2026 Pharma R&D AI Sourcing Map: Partnerships, Concentration, Inflection
A Beroe analysis of 2026 pharma AI deals shows discovery still dominates, suppliers are consolidating, and clinical development is the next AI sourcing frontier.
-
Lupus Researchers Now Have A Three-Pillar RWD Platform To Support Discovery And Development
Lupus Nexus unites a registry, biorepository, and data exchange to give researchers longitudinal real-world data without building the infrastructure from scratch.
-
Novel Science, Familiar Regulatory Pathways: Inside Tonix's Clinical Development Strategy
Tonix CEO Seth Lederman, MD, explains how the company pairs novel science with proven regulatory paths across fibromyalgia, depression, and Lyme disease.
-
As U.S. Trial Share Slips, A Coalition Maps A Path To Broader Patient Access
Milken Institute's Kristin Schneeman explains how a new action plan could broaden patient access in the U.S. — and what sponsors and policymakers can do now.
-
A Window Into Aging: Why Skin Is the First Test For RLS-1496
Rubedo’s Marco Quarta explains how patient selection, controls, biopsies, and biomarkers shaped early RLS-1496 trial protocols.
-
Brazil's Regulatory Transformation: Building And Supporting Sites Beyond The AMCs
Our expert chat about Brazil’s clinical research transformation concludes with SBOC President-elect Fabio Franke, who explores building sustainable trial capacity beyond the country’s major AMCs.
-
Brazil's Regulatory Transformation: Expanding Clinical Trial Participation
A discussion of Brazil’s clinical research transformation continues as this Q&A series turns to Maiko L. Tonini, Ph.D., of Brazil’s Ministry of Health, to explore expanding clinical trial participation.
CLINICAL TRIAL WHITE PAPERS
-
Advancing Alzheimer's Disease Therapies
By uniting scientific innovation with patient-focused execution, the next generation of alzheimer’s disease (AD) therapies has the potential to deliver a transformative impact on global health.
-
Innovating With Generative And Agentic Artificial Intelligence3/30/2026
Discover how specialized AI is revolutionizing clinical trials by enhancing data quality and operational speed through curated training, human oversight, and objective scientific analysis.
-
What Is ICH GCP, And How Does It Impact Clinical Planning?10/20/2025
The updated ICH GCP guideline modernizes clinical trial standards, aligning with today’s technologies to enhance participant safety, data integrity, and risk-based trial design.
-
Effectively Tailoring Treatments Based On Genetic & Molecular Profiling9/30/2026
Precision medicine is transforming hematology-oncology care by matching treatments to the distinct genetic and molecular profiles of each patient.
-
ICH GCP E6(R3) Implementation: Practical Approaches And Real-World Considerations11/21/2025
Access the full brief to learn how a phased, 12–18-month approach can help you meet ICH GCP E6(R3) requirements with confidence and avoid the costly pitfalls many organizations overlook.
-
Navigating Complexity In Master Protocols With Key Operational Partners7/5/2026
Complex adaptive trials offer real efficiency gains, but success hinges on having experienced partners to manage the operational details.
CLINICAL TRIAL APP NOTES & CASE STUDIES
-
Driving A High-Adherence LTFU Trial Without An EDC10/29/2025
Discover how our partnership with a client was able to deliver a ten-year long-term follow-up (LTFU) trial that delivered an over 90% adherence rate while keeping trial costs low by not using an EDC.
-
What Unified eCOA And IRT Can Unlock4/6/2026
See how real-time scoring and automated eligibility checks helped a global dermatology study reduce site burden, avoid manual errors, and move participants through screening with greater speed.
-
CRO Takes Trial Build Times From Weeks To Days5/27/2025
Recognizing the inefficiencies in traditional build processes, a top global CRO partnered with Medable to transform its approach to clinical trial launch.
-
Scaling Success: A Blueprint For Flexible Biometrics Partnerships2/19/2026
Learn how a micro-FSP model and integrated biometrics team can scale from specialized support to a full-service solution, ensuring agility and consistency as clinical trial needs evolve.
-
Relieving Pressure During Preparation Of A High-Volume sNDA5/27/2026
Managing a complex sNDA under pressure? See how one sponsor achieved an early FDA submission through coordinated publishing, regulatory strategy, and flawless execution.
-
Setting A New Client Standard In Study Closeout Timelines4/4/2025
Learn how a top-10 global pharmaceutical company achieved a significantly faster time to market for a high-profile therapy.
NEWSLETTER ARCHIVE
- 11.20.26 -- Oversight Monitoring In Clinical Trials
- 11.20.26 -- Overloaded Sites, Stalled Enrollment, Lost Patients: Where Trial Execution Breaks Down
- 11.19.26 -- A New Era For Clinical Development For Brazil
- 11.18.26 -- Lab Logistics: Delivering The Complex Without Compromise
- 11.18.26 -- Sponsors Can Drown In Data As Patient Diversity Gaps Persist
RECRUITMENT AND DIVERSITY
This section includes some helpful resources regarding patient recruitment and diversity in clinical trials, including this link to the FDA's guidance on diversity action plans.
-
Recruitment problems can start long before actual recruitment. Who is making sure your team gets ahead of those challenges?
-
Lupus Nexus unites a registry, biorepository, and data exchange to give researchers longitudinal real-world data without building the infrastructure from scratch.
-
Milken Institute's Kristin Schneeman explains how a new action plan could broaden patient access in the U.S. — and what sponsors and policymakers can do now.
FOCUS ON PATIENTS
-
Milken Institute's Kristin Schneeman explains how a new action plan could broaden patient access in the U.S. — and what sponsors and policymakers can do now.
-
Clinical trial patients may need care outside of the trial protocol. Discover how closing information gaps can protect safety, trial participation, and data integrity.
-
Can early APG-157 treatment control head and neck cancer without delaying curative care? A Phase 3 trial puts timing, safety, and outcomes to the test.
EDITORIAL COLLECTIONS
Take a deep dive into the issues shaping clinical research today with our curated Editorial Collections. Each collection features expert insights and practical strategies addressing today’s biggest challenges in clinical trial planning and execution.
More Editorial Collections
